[Elsevier]
Challenge-mig: a phase 4, randomized, double-blind, double-dummy study comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine
Authors£ºTodd J. Schwedt; Tina M. Myers Oakes; James M. Martinez; Bert B. Vargas; Hitendra N. Pandey; Eric M. Pearlman; Diane R. Richardson; Oralee J. Varnado; Michael Cobas Meyer; Peter J. Goadsby